SCHEMBL222259

SCHEMBL222259

C[C@@H](OC(=O)[C@@H](N)CCCCN)[C@H](N)C(=O)O.NCCCC[C@H](N)C(=O)OC(=O)[C@@H](N)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.46
ALPI P09923 1/20 0.43
PKM P14618 1/20 0.43
PTGS1 P23219 1/20 0.43
XIAP P98170 1/20 0.43
SLC7A5 Q01650 1/20 0.43
ANPEP P15144 2/20 0.42
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
RNPEP Q9H4A4 1/20 0.40
DNPEP Q9ULA0 1/20 0.40
LTA4H P09960 2/20 0.40
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
DAGLA Q9Y4D2 1/20 0.40
THRB P10828 1/20 0.39
ERAP2 Q6P179 1/20 0.39
LNPEP Q9UIQ6 1/20 0.39
GSR P00390 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylalanine SCHEMBL6130124 0.93 SLC7A5 (0.51) MMP2ALPIPKMPTGS1XIAP
Tyrosine SCHEMBL11404581 0.87 SLC7A5 (0.49) MMP2ALPIPKMPTGS1XIAP
SCHEMBL237821 0.87 MMP2 (0.58) MMP2ALPIPKMPTGS1XIAP
SCHEMBL1537425 0.87 MMP2 (0.58) MMP2ALPIPKMPTGS1XIAP
SCHEMBL4586624 0.86 ALPI (0.57) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL1537320 0.83 ALPI (0.53) MMP2ALPIPKMPTGS1XIAP
SCHEMBL1162106 0.83 GSR (0.55) SLC7A5RNPEPGSRCPB2
SCHEMBL4255881 0.82 GSR (0.45) RNPEPTHRBGSRCPB2
SCHEMBL2684557 0.80 GSR (0.43) RNPEPGSRCPB2
SCHEMBL14434512 0.78 ERAP2 (0.44) ALPIPKMPTGS1XIAPSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849840-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin NEW AVON LLC (US) 2020-12-01 US claimed
EP-3272329-B1 COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN AVON PROD INC (US) 2020-09-16 EP claimed
US-10849840-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin NEW AVON LLC (US) 2020-12-01 US disclosed
EP-3272329-B1 COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN AVON PROD INC (US) 2020-09-16 EP disclosed
US-20180271772-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin AVON PRODUCTS, INC 2018-09-27 US disclosed
US-9999587-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin AVON PRODUCTS, INC. (US) 2018-06-19 US disclosed
EP-3272329-A2 COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN Avon Products, Inc. (US) 2018-01-24 EP disclosed
EP-2588593-B1 COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN AVON PROD INC (US) 2017-08-23 EP disclosed
US-20160008266-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin CITIBANK, N.A., LONDON BRANCH 2016-01-14 US disclosed
US-9132294-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin AVON PRODUCTS, INC. (US) 2015-09-15 US disclosed
EP-2588593-A2 COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN Avon Products, Inc. (US) 2013-05-08 EP disclosed
WO-2012005876-A2 COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN AVON PRODUCTS, INC. (US) 2012-01-12 WO disclosed
US-20120003332-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin AVON PRODUCTS, INC. (US) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180271772-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin MAG, MFAP1, CUTA MMP2 1123/4885ALPI 4488/4885PKM 4728/4885
US-20160008266-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin MAG, MFAP1, CUTA MMP2 1123/4885ALPI 4488/4885PKM 4728/4885
US-10849840-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin MAG, MFAP1, CUTA MMP2 1123/4885ALPI 4488/4885PKM 4728/4885
US-20120003332-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin MAG, MFAP1, CUTA MMP2 1123/4885ALPI 4488/4885PKM 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.